Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know
05:15am, Thursday, 13'th Nov 2025
These two healthcare giants have impressive growth potential for different reasons. Eli Lilly is getting a lot of attention for its GLP-1 successes, and another blockbuster could be just around the co
Final Trade: LMAT, REGN, BA, TJX
06:20pm, Wednesday, 12'th Nov 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice Pr
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Regeneron Announces Investor Conference Presentations
04:05pm, Monday, 03'rd Nov 2025
TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
07:00am, Friday, 31'st Oct 2025
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions
D.A. Davidson & CO. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
04:08am, Friday, 31'st Oct 2025
D.A. Davidson and CO. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 16.8% during the second quarter, according to its most recent 13F filing with the Securities a
Pharmaceutical Stocks To Keep An Eye On – October 28th
02:09am, Thursday, 30'th Oct 2025
Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock
Top Medical Stocks To Research – October 28th
02:09am, Thursday, 30'th Oct 2025
UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback
01:00pm, Wednesday, 29'th Oct 2025
Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by Dup
Market Starting To Embrace The 'New' Regeneron
12:01pm, Wednesday, 29'th Oct 2025
Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact the Eylea franchise is no longer a growth product. Eylea franchise faces o
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
04:05pm, Tuesday, 28'th Oct 2025
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
01:31pm, Tuesday, 28'th Oct 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leo
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
10:36am, Tuesday, 28'th Oct 2025
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall S
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
09:13am, Tuesday, 28'th Oct 2025
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.
